| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 80 | 2024 | 463 | 10.340 |
Why?
|
| Breast Neoplasms | 67 | 2024 | 2903 | 5.170 |
Why?
|
| Calcinosis | 38 | 2018 | 224 | 3.930 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 36 | 2017 | 466 | 3.650 |
Why?
|
| Radiographic Image Enhancement | 38 | 2018 | 462 | 3.120 |
Why?
|
| Diagnosis, Computer-Assisted | 30 | 2022 | 332 | 3.030 |
Why?
|
| Algorithms | 34 | 2024 | 1830 | 2.420 |
Why?
|
| Breast Diseases | 22 | 2017 | 97 | 2.360 |
Why?
|
| Pattern Recognition, Automated | 12 | 2014 | 217 | 2.220 |
Why?
|
| Breast | 11 | 2024 | 288 | 1.970 |
Why?
|
| ROC Curve | 21 | 2024 | 752 | 1.410 |
Why?
|
| Sensitivity and Specificity | 37 | 2018 | 1991 | 1.390 |
Why?
|
| Image Interpretation, Computer-Assisted | 8 | 2015 | 663 | 1.340 |
Why?
|
| Mass Screening | 8 | 2023 | 618 | 1.220 |
Why?
|
| Artificial Intelligence | 12 | 2023 | 298 | 1.170 |
Why?
|
| Reproducibility of Results | 31 | 2017 | 2705 | 1.100 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2018 | 1204 | 0.960 |
Why?
|
| X-Ray Film | 4 | 2012 | 36 | 0.820 |
Why?
|
| Precancerous Conditions | 6 | 2006 | 196 | 0.820 |
Why?
|
| Models, Statistical | 5 | 2013 | 574 | 0.810 |
Why?
|
| Imaging, Three-Dimensional | 8 | 2015 | 579 | 0.770 |
Why?
|
| Female | 76 | 2024 | 44532 | 0.760 |
Why?
|
| Models, Biological | 5 | 2013 | 1749 | 0.730 |
Why?
|
| Breast Density | 2 | 2018 | 31 | 0.670 |
Why?
|
| Humans | 102 | 2024 | 86643 | 0.650 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 394 | 0.640 |
Why?
|
| Information Storage and Retrieval | 5 | 2012 | 120 | 0.550 |
Why?
|
| Machine Learning | 1 | 2017 | 232 | 0.530 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2013 | 27 | 0.460 |
Why?
|
| Chemokine CXCL1 | 1 | 2012 | 9 | 0.420 |
Why?
|
| Preventive Health Services | 1 | 2011 | 37 | 0.410 |
Why?
|
| X-Ray Intensifying Screens | 6 | 2012 | 32 | 0.390 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 160 | 0.380 |
Why?
|
| Observer Variation | 9 | 2013 | 602 | 0.380 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 469 | 0.370 |
Why?
|
| Computer Simulation | 6 | 2015 | 1078 | 0.360 |
Why?
|
| Image Enhancement | 5 | 2016 | 563 | 0.350 |
Why?
|
| Data Display | 1 | 2009 | 24 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.340 |
Why?
|
| Carcinoma | 1 | 2012 | 436 | 0.320 |
Why?
|
| Biophysics | 7 | 2002 | 152 | 0.300 |
Why?
|
| Subtraction Technique | 3 | 2005 | 133 | 0.290 |
Why?
|
| Radiologists | 2 | 2023 | 46 | 0.280 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 86 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2017 | 2601 | 0.270 |
Why?
|
| Artifacts | 3 | 2006 | 244 | 0.260 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 744 | 0.260 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 151 | 0.260 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1464 | 0.230 |
Why?
|
| Phantoms, Imaging | 4 | 2013 | 429 | 0.210 |
Why?
|
| Medicine | 1 | 2022 | 89 | 0.210 |
Why?
|
| False Positive Reactions | 10 | 2002 | 216 | 0.200 |
Why?
|
| Cluster Analysis | 5 | 2010 | 369 | 0.190 |
Why?
|
| Research Design | 2 | 2017 | 594 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1805 | 0.180 |
Why?
|
| Contrast Media | 2 | 2016 | 1078 | 0.180 |
Why?
|
| Software | 3 | 2013 | 654 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8489 | 0.160 |
Why?
|
| Radiology | 4 | 2014 | 194 | 0.160 |
Why?
|
| Automation | 2 | 2018 | 106 | 0.160 |
Why?
|
| Models, Theoretical | 5 | 2010 | 482 | 0.160 |
Why?
|
| Government Regulation | 1 | 2017 | 49 | 0.150 |
Why?
|
| Likelihood Functions | 3 | 2010 | 251 | 0.150 |
Why?
|
| Fourier Analysis | 3 | 2011 | 125 | 0.150 |
Why?
|
| Radiography, Thoracic | 6 | 2002 | 320 | 0.150 |
Why?
|
| Conflict of Interest | 1 | 2017 | 67 | 0.150 |
Why?
|
| Bias | 1 | 2017 | 127 | 0.140 |
Why?
|
| Equipment Failure Analysis | 2 | 2009 | 90 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2016 | 334 | 0.140 |
Why?
|
| Databases, Factual | 9 | 2018 | 814 | 0.130 |
Why?
|
| X-Rays | 3 | 2013 | 130 | 0.130 |
Why?
|
| Physicians | 1 | 2022 | 673 | 0.130 |
Why?
|
| Registries | 1 | 2018 | 702 | 0.130 |
Why?
|
| Iodine | 1 | 2012 | 43 | 0.110 |
Why?
|
| Symporters | 1 | 2012 | 107 | 0.110 |
Why?
|
| Ovarian Cysts | 1 | 2012 | 17 | 0.110 |
Why?
|
| Biopsy | 3 | 2013 | 1163 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 328 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 1565 | 0.100 |
Why?
|
| Nipples | 1 | 2011 | 37 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.100 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2012 | 62 | 0.100 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2012 | 43 | 0.100 |
Why?
|
| United States | 4 | 2018 | 6672 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 307 | 0.100 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2010 | 201 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2015 | 428 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 376 | 0.100 |
Why?
|
| Hemangioma | 1 | 2010 | 60 | 0.090 |
Why?
|
| Photons | 1 | 2010 | 46 | 0.090 |
Why?
|
| Tomography, X-Ray | 1 | 2009 | 18 | 0.090 |
Why?
|
| Radionuclide Imaging | 2 | 2006 | 220 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2014 | 751 | 0.090 |
Why?
|
| Computer Systems | 3 | 2000 | 79 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 449 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1186 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 406 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 359 | 0.080 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2008 | 64 | 0.080 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 14 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 84 | 0.070 |
Why?
|
| Discrimination Learning | 1 | 2006 | 63 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 297 | 0.070 |
Why?
|
| Glioma | 1 | 2007 | 285 | 0.060 |
Why?
|
| Middle Aged | 7 | 2016 | 25028 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3362 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 5 | 1998 | 274 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 736 | 0.060 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2002 | 138 | 0.060 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 99 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 429 | 0.060 |
Why?
|
| Bone Density | 1 | 2004 | 209 | 0.060 |
Why?
|
| Medical Audit | 1 | 2022 | 41 | 0.060 |
Why?
|
| Mathematics | 3 | 1995 | 190 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 220 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 133 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1169 | 0.050 |
Why?
|
| Fuzzy Logic | 1 | 2000 | 15 | 0.050 |
Why?
|
| Neoplasms | 1 | 2015 | 2898 | 0.050 |
Why?
|
| Biophysical Phenomena | 5 | 1998 | 120 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Prognosis | 1 | 2006 | 3679 | 0.040 |
Why?
|
| Angiography | 3 | 1995 | 208 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 1996 | 763 | 0.040 |
Why?
|
| Scattering, Radiation | 2 | 2013 | 114 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 839 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2017 | 66 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2014 | 912 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2018 | 219 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 127 | 0.040 |
Why?
|
| Eye | 1 | 1997 | 111 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2007 | 3241 | 0.040 |
Why?
|
| Adult | 6 | 2016 | 25648 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2016 | 25 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1996 | 39 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1996 | 100 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 636 | 0.030 |
Why?
|
| Copying Processes | 1 | 1994 | 6 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 813 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 5417 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1996 | 255 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 304 | 0.030 |
Why?
|
| Expert Systems | 1 | 1993 | 18 | 0.030 |
Why?
|
| Georgia | 1 | 2012 | 34 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2002 | 2262 | 0.030 |
Why?
|
| Lasers | 1 | 1992 | 106 | 0.030 |
Why?
|
| Technology, Radiologic | 2 | 1998 | 103 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2013 | 240 | 0.020 |
Why?
|
| Quantum Theory | 1 | 1989 | 28 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 1989 | 27 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 1994 | 227 | 0.020 |
Why?
|
| Health Physics | 1 | 1989 | 18 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1989 | 57 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Aged | 4 | 2012 | 18415 | 0.020 |
Why?
|
| Butadienes | 1 | 2007 | 33 | 0.020 |
Why?
|
| Carcinoma, Ductal | 1 | 2007 | 18 | 0.020 |
Why?
|
| Nitriles | 1 | 2007 | 149 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 115 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2007 | 268 | 0.020 |
Why?
|
| Radiology Information Systems | 2 | 1999 | 76 | 0.020 |
Why?
|
| Models, Structural | 1 | 1986 | 58 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1990 | 426 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2007 | 289 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 363 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 157 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 199 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 269 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 896 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 547 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1990 | 621 | 0.020 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 6509 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 353 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2004 | 41 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2004 | 100 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2007 | 1106 | 0.020 |
Why?
|
| Radiometry | 1 | 2004 | 53 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 4213 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 639 | 0.010 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2004 | 103 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2004 | 185 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2001 | 3640 | 0.010 |
Why?
|
| Methylmethacrylate | 2 | 1996 | 6 | 0.010 |
Why?
|
| Methylmethacrylates | 2 | 1996 | 8 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1531 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2468 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 1197 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2426 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1578 | 0.010 |
Why?
|
| Fibrocystic Breast Disease | 1 | 1999 | 12 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1801 | 0.010 |
Why?
|
| Fibroadenoma | 1 | 1999 | 9 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 63 | 0.010 |
Why?
|
| Male | 4 | 2010 | 40965 | 0.010 |
Why?
|
| Colloids | 1 | 1996 | 25 | 0.010 |
Why?
|
| Lead | 1 | 1996 | 26 | 0.010 |
Why?
|
| Age Distribution | 1 | 1996 | 204 | 0.010 |
Why?
|
| Printing | 1 | 1994 | 4 | 0.010 |
Why?
|
| Densitometry | 1 | 1994 | 29 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1996 | 164 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 364 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1995 | 265 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 11352 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1996 | 266 | 0.010 |
Why?
|
| Comorbidity | 1 | 1996 | 943 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1993 | 232 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1993 | 123 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1996 | 383 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1993 | 263 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 5210 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 1169 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 26582 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 1686 | 0.000 |
Why?
|
| Survival Rate | 1 | 1990 | 1863 | 0.000 |
Why?
|
| Epoxy Resins | 1 | 1986 | 1 | 0.000 |
Why?
|
| Computers | 1 | 1986 | 112 | 0.000 |
Why?
|
| Quality Control | 1 | 1986 | 117 | 0.000 |
Why?
|
| Brain | 1 | 1990 | 2216 | 0.000 |
Why?
|